ICRN/ENS-CCA Translational Science Seminar Series
The Seminar Series is a tool to disseminate emerging basic, translational, and clinical information to interested researchers around the globe with hope of fostering new ideas and deeper collaborations among our membership.
We encourage all ICRN/ENS-CCA Members to participate as a speaker in the ICRN/ENS-CCA Translational Science Seminar Series. If you’d like to present, please contact us
Upcoming Presentation
March 2, 2026, 9:00am (EST)
ICRN/ENS-CCA Translational Science Seminar Series: Translating HER2-Directed Therapy in Biliary Tract Cancer.
The webinar will run for 1 hour and will include a mixture of presentations and frequent interactions from the chairs, allowing for an interactive session. Attendees can ask questions, either spoken or submitted, using the chat function. This session will be recorded for future reference. Attendance certificates will be provided for attendees of live sessions.
Past Presentations
September 2025: Digital & Biological Twins in CCA-From Translational Research to Precision Medicine
March 2025: PSC-related Cholangiocarcinoma – Part 2, Translational Aspects and Therapy
December 2024: PSC-related Cholangiocarcinoma – Part 1, Screening Prevention and Early Diagnosis
September 2024: Breaking New Ground – Advances in Oncolytic Virus Therapy for Cholangiocarcinoma
January 2024: KRAS as a therapeutic target in cholangiocarcinoma
July 2022: Morphomolecular characterization of early and progressed cholangiocarcinoma
June 2022: Opportunities for Innovative Radiopharmaceutical Diagnostics and Therapeutics Discovery for Cholangiocarcinoma
May 2022: Deciphering the role of ZEB1 in the tumor-stroma crosstalk in cholangiocarcinoma
April 2022: Supermassive Intrahepatic CCA: Clinicogenomic Analysis & Role of Ablative Radiotherapy
March 2022: Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models
February 2022: Targeting Immunosuppressive Myeloid Cells in Cholangiocarcinoma
December 2021: Challenges of Designing Immune Trials in the Second Line with a Review of Data
October 2021: PSC & cholangiocarcinoma – where the research stands on the interconnection
September 2021: Genomic and Epigenomic Landscape of Cholangiocarcinoma – Cancer Discovery Paper Discussion
August 2021: Genomic and Epigenomic Landscape of Cholangiocarcinoma – Cancer Discovery Paper Discussion
July 2021: Role of Cytotoxic Chemo in Cholangiocarcinoma
June 2021: Next Steps with FGFRi
May 2021: The Cholangiocarcinoma Participant Engagement and Cancer Genome Sequencing U2C Cancer Moonshot Program at Washington University in St. Louis Collapse
April 2021: What is IDH1 mutated cholangiocarcinoma and what else can we do for it?
March 2021: Innovative surgical approaches to cholangiocarcinoma – transplant and beyond
February 2021: MEKi – Where do we go next in cholangiocarcinoma?
January 2021: Ciliotherapy: The Primary Cilium as a Therapeutic Target in Carcinogenesis
December 2020: ARID1A and CCA
November 2020: Introduction to cBioPortal for Cancer Genomics
October 2020: Ablative Radiation for Intrahepatic Cholangiocarcinoma: Current Status and Future Directions
September 2020: Drug Repurposing in Cholangiocarcinoma – Identifying Leads from the Literature
August 2020: Immune Landscape of Cholangiocarcinoma
